At Prellis Biologics we are dedicated to ending the global human organ shortage by building real medical solutions that leverage the power of human cells to re-create tissues and organs for transplantation. Our ability to produce biomimetic tissue scaffolds allows us to access the power of human tissues, outside of the body, to rapidly and efficiently specific human antibodies, and albumin in the laboratory setting.
Prellis Biologics, Inc was founded with the optical path for a novel form of lithography based on holographic projection sketched out in my San Francisco home office. A few months after filing the patents we were able to demonstrate that the system worked as designed and began the scale-up process, achieving over 500,000 printed voxels per second with only off-the-shelf optical equipment.
This laser printing technology represents the first known example of free-form printing that significantly decouples printing resolution from speed.
Since then the Prellis Team has built a high-power holographic laser printing system for biocompatible materials, companion software, and novel photo-quenching chemistry, that together, has solved the final technical hurdle in printing and producing human organ systems and tissues: building the capillaries that allow tissues to function.
Prellis Biologics, Inc was founded with the optical path for a novel form of lithography based on holographic projection sketched out in my San Francisco home office. A few months after filing the patents we were able to demonstrate that the system worked as designed and began the scale-up process, achieving over 500,000 printed voxels per second with only off-the-shelf optical equipment.
This laser printing technology represents the first known example of free-form printing that significantly decouples printing resolution from speed.
Since then the Prellis Team has built a high-power holographic laser printing system for biocompatible materials, companion software, and novel photo-quenching chemistry, that together, has solved the final technical hurdle in printing and producing human organ systems and tissues: building the capillaries that allow tissues to function.
Location: United States, California, Hayward
Employees: 11-50
Total raised: $70.8M
Founded date: 2016
Investors 8
| Date | Name | Website |
| 27.08.2022 | Black Diam... | bdventures... |
| 20.04.2022 | Khosla Ven... | khoslavent... |
| 11.01.2022 | Civilizati... | civilizati... |
| - | MBC BioLab... | mbcbiolabs... |
| 12.05.2021 | Lucas Vent... | lucasvg.co... |
| - | Cantos Ven... | cantos.vc |
| 07.08.2022 | Celesta Ca... | celesta.vc |
| - | Prefix Cap... | prefixcapi... |
Funding Rounds 5
| Date | Series | Amount | Investors |
| 11.08.2022 | Series C | $35M | - |
| 15.12.2021 | Series B | $14.5M | - |
| 12.08.2019 | Series A | $10.5M | - |
| 28.03.2019 | - | $9M | - |
| 13.09.2017 | Seed | $1.8M | - |
Mentions in press and media 29
| Date | Title | Description |
| 04.12.2025 | Lyric Bio: $6.6 Million Seed Funding Closed To Advance Donor-Derived Therapeutics | Lyric Bio, a San Carlos–based biomanufacturing startup spun out of Prellis Biologics, has raised $6.6 million in oversubscribed seed financing to scale its next-generation production platform for donor-derived therapeutics. The round was le... |
| 16.04.2024 | SOSV Closes $306M Deep Tech Fund for Human and Planetary Health | PRINCETON, N.J., April 16, 2024 /PRNewswire/ -- SOSV, a multi-stage deep tech venture investor, today announced the close of its $306 million SOSV V fund, the firm's largest fund to date. SOSV V will focus on deep tech startups in human and... |
| 05.01.2023 | CollPlant’s 3D bioprinted breast implants achieve “promising results” in animal testing | Regenerative medicine specialist CollPlant has announced that its proprietary 3D bioprinted breast implants have successfully passed animal testing. Bioprinted from ‘rhCollagen,’ a plant-based alternative to human collagen, CollPlant’s impl... |
| 28.09.2022 | Innovative 3D printing-enabled strain sensor unlocks real-time monitoring of cancerous tumors | Researchers at Stanford University have used 3D printing to develop a strain sensor that enables the wireless monitoring of tumor regression in cancer patients. Composed of a 50-nm layer of gold, drop-casted onto a flexible polymer enclosed... |
| 09.09.2022 | 3D Systems spins off new 3D bioprinting firm with goal of accelerating drug discovery R&D | US 3D printer manufacturer 3D Systems has announced the formation of a new 3D bioprinting subsidiary. Named Systemic Bio, the company is set to utilize the technologies developed as part of its parent firm’s Print to Perfusion program as we... |
| 11.08.2022 | Prellis Biologics hires new CEO, raises $35M towards 3D bioprinted lymph node R&D | Prellis Biologics has raised $35 million and appointed a new CEO as it seeks to advance the development of its proprietary 3D bioprinted lymph node. Raised via a Series C funding round led by Celesta Capital and Avidity Partners, and backed... |
| 10.08.2022 | Prellis Biologics Raises $35M in Series C Funding | Prellis Biologics, a San Francisco, CA-based biotherapeutics company, raised $35M in Series C funding. The round, which brings funding to date to $64.5m, was led by Celesta Capital and Avidity Partners with participation from Khosla Venture... |
| 10.08.2022 | “Prellis Biologics Appoints New CEO, Raises $35 Million in Series C Funding to Leverage Human Immune System Biology to De-Risk and Accelerate Therapeutics Drug Discovery and Development” | - |
| 20.12.2021 | Prellis Biologics 3D bioprints lymph node to unlock antibody discovery at pace | Biotechnology firm Prellis Biologics has announced the closure of a $14.5 million Series B funding round alongside the creation of a novel antibody discovery platform. Effectively a functioning immune system in a dish, the firm’s platform i... |
| 15.12.2021 | Prellis Biologics Launches In Vitro Human Antibody Discovery Platform, Announces $14.5 Million Series B Investment, Key Executive Hires | SAN FRANCISCO (PRWEB) December 15, 2021 Prellis Biologics announced today that it has closed a $14.5 million Series B financing round, led by Celesta Capital and current investor Khosla Ventures Prellis will use the proceeds to advance its ... |
Show more